Przegląd Dermatologiczny

Full text

2/2026 vol. 113
Letter to the Editor

Relapse after Excision of Melanoma in situ

Faruk Tas 1

  1. Institute of Oncology, Istanbul University, Turkey

Dermatol Rev/Przegl Dermatol 2026, 113, 107–108

DOI: https://doi.org/10.5114/dr.2026.163248
Data publikacji online: 2026/07/31
Article file
Relapse after.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Patel V.R., Roberson M.L., Pignone M.P., Adamson A.S.: Risk of mortality after a diagnosis of melanoma in situ. JAMA Dermatol 2023, 159, 703-710.
  2. Naeser Y., Mikiver R., Ingvar C., Lambe M., Ullenhag G.J.: Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study. EClinicalMedicine 2023, 65, 102284.
  3. Mikkelsen J., Wagenblast A.L.H., Behrendt N., Lock-Andersen J.: Melanoma in situ with in-transit metastases. JPRAS Open 2017, 11, 37-42.
  4. Anderson J., Hamp A., Booms A., Carlson S.K.: Metastasis of a surgically excised melanoma in situ. J Dermatol Nurses Assoc 2022, 14, 170-172.
  5. Pantaleão L., Rochael M.C.: Study of 448 cases of melanoma in situ in two hospitals in Rio de Janeiro. An Bras Dermatol 2017, 92, 277-278.
  6. Bax M.J., Johnson T.M., Harms P.W., Schwartz J.L., Zhao L., Fullen D.R.: Detection of occult invasion in melanoma in situ. JAMA Dermatol 2016, 152, 1201-1208.
  7. Moyer J.S., Rudy S., Boonstra P.S., Kraft C., Chinn S.B., Baker S.R., et al.: Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol 2017, 153, 282-288.
  8. Higgins H.W., Lee K.C., Galan A., Leffell D.J.: Melanoma in situ: part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol 2015, 73, 193-203.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Indeks osobowy
Share
without publication fees
without publication fees
Coverage in
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications